INTECH Investment Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

INTECH Investment Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$915K	Buy	24,453 +912	+4%	+$33.9K	0.01%	1076
2026 Q1	$855K	Sell	23,541 -6,702	-22%	-$299K	0.01%	1077
2025 Q4	$1.41M	Buy	30,243 +8,018	+36%	+$357K	0.01%	934
2025 Q3	$926K	Sell	22,225 -20,408	-48%	-$653K	0.01%	1211
2025 Q2	$1.23M	Sell	42,633 -14,317	-25%	-$442K	0.01%	1081
2025 Q1	$1.91M	Buy	56,950 +13,845	+32%	+$517K	0.02%	779
2024 Q4	$2.2M	Buy	43,105 +20,757	+93%	+$1.16M	0.02%	658
2024 Q3	$1.14M	Buy	+22,348	New	+$1.15M	0.01%	732

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

INTECH Investment Management's CRNX Position: Q2 2026 in Review

INTECH Investment Management increased its Crinetics Pharmaceuticals (CRNX) stake by 3.9% in Q2 2026, buying an estimated $33.9K and bringing the position to 24,453 shares worth $915K. The position accounts for 0.01% of the portfolio, ranked #1076.

INTECH Investment Management first reported a position in CRNX in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.2M in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

INTECH Investment Management held 24,453 shares of Crinetics Pharmaceuticals worth $915K as of Q2 2026.
INTECH Investment Management bought 912 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $33.9K.
Crinetics Pharmaceuticals made up 0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1076 holding.
INTECH Investment Management first reported a position in Crinetics Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
INTECH Investment Management's Crinetics Pharmaceuticals position peaked at $2.2M in Q4 2024.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.